ABNX.PA (ABNX.PA) Stock Analysis

Verdict: AVOID

Dwindling cash runway (~13 months) and declining revenues force severe equity dilution risk, keeping the stock anchored near 52-week lows.

Investment score: 26/100

Is ABNX.PA Stock Worth Reviewing? AI Model Thesis

The AI model views ABIONYX Pharma as an AVOID due to an acute ~13-month cash runway ($3.52M cash vs $3.18M annual FCF burn), contracting revenues ($4.06M in 2025 vs $5.25M in 2022), and impending dilution risk.

Should You Buy or Sell ABNX.PA Stock? Model Reasoning

ABIONYX faces severe balance sheet pressure with $3.52M in cash remaining against an annual cash burn of $3.18M. With total debt of $3.81M surpassing liquid cash and revenue declining by 22.6% since 2022, the model sees a high probability of substantial equity dilution within 12 months.

ABNX.PA Fair Value & Price Target — AI Valuation

  • Model Assumptions: ["Annual FCF burn remains steady at $3.18M to $3.50M per year","Dilution of 20-30% in equity shares required within 12 months to fund clinical operations","No upfront milestone payments from licensing partners prior to H2 2026"]

ABNX.PA Risk & Opportunity Analysis

Key Investment Risks

  • Imminent cash runway depletion driving heavy equity dilution — With $3.52M cash as of Dec 2025 and -$3.18M annual FCF, dilutive share issuance or convertible financing will be necessary by late 2026.
  • Sustained top-line contraction from legacy products — Revenue dropped from $5.25M in 2022 to $4.06M in 2025; ongoing weakness accelerates cash burn.
  • Clinical trial setback or adverse safety signal for CER-001 — Single-candidate concentration in CER-001 means negative phase trial results could pull equity valuation down toward net book value ($4.51M).
  • Severe illiquidity and execution risk on secondary exchanges — Low average daily volume on Euronext Paris causes execution slippage and rapid price drops on minor sell orders below 1.88 USD.

Growth Opportunities & Upside Drivers

  • Positive clinical data readout for CER-001 in renal or sepsis indications — Favorable trial results could secure non-dilutive licensing capital or strategic partnerships by late 2026.
  • Recombinant bio-HDL platform expansion across CER-002 and CER-209 — Broadening indication scope could increase enterprise valuation beyond the current $85.3M market capitalization.
  • Tactical oversold bounce off the 52-week low support of 1.88 USD — A 41.6% 90-day drawdown creates scope for short-term technical mean reversion toward resistance at 2.80 USD.
  • M&A interest from larger renal or cardiovascular pharmaceutical biotechs — Proprietary bioproduction partnerships with GTP Biologics make ABIONYX a niche acquisition candidate.

ABNX.PA Action Plan — Entry, Exit and Stop Loss from the Model View

moderate

    aggressive

      conservative

        Frequently Asked Questions About ABNX.PA (ABNX.PA)

        Is ABNX.PA stock a good investment?

        The cached TradeMates AI model rates ABNX.PA as AVOID with an investment score of 26/100. The AI model views ABIONYX Pharma as an AVOID due to an acute ~13-month cash runway ($3.52M cash vs $3.18M annual FCF burn), contracting revenues ($4.06M in 2025 vs $5.25M in 2022), and impending dilution risk. This is algorithmic model output, not personal investment advice.

        Does ABNX.PA pay a dividend?

        The cached stock data on this page does not show a positive dividend yield for ABNX.PA. Dividend status can change, so verify the latest company filings before relying on income assumptions.

        What does ABNX.PA stock do?

        ABIONYX Pharma S.A. operates as a clinical-stage biotechnology company focused on recombinant apoA-I bio-HDL therapies (lead candidate CER-001). Commercial revenues are generated primarily through specialized bioproduction services and contract research, while the core clinical pipeline remains pre-commercial.

        What is ABNX.PA stock's price target?

        This cached page does not contain a precise model fair value for ABNX.PA.

        Is ABNX.PA stock a buy?

        The TradeMates model verdict for ABNX.PA is AVOID with an investment score of 26/100. Treat this as a model signal to review, not a personal buy recommendation.

        Is ABNX.PA a good dividend stock?

        ABNX.PA is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

        View the full interactive analysis